Abstract
BackgroundThe cisplatin-resistance is still a main course for chemotherapy failure of lung cancer patients. Cisplatin-resistant cancer cells own higher malignance and exhibited increased metastatic ability, but the mechanism is not clear. In this study, we investigated the effects of Ataxia Telangiectasia Mutated (ATM) on lung cancer metastasis.Materials and methodsCisplatin-resistant A549CisR and H157CisR cell line were generated by long-term treating parental A549 and H157 cells (A549P and H157P) with cisplatin. Cell growth, cell migration and cell invasion were determined. Gene expressions were determined by Western Blot and qPCR. Tumor metastasis was investigated using a xenograft mouse model.ResultsThe IC50 of the cisplatin-resistant cells (A549CisR and H157CisR cells) to cisplatin was 6–8 higher than parental cells. The A549CisR and H157CisR cells expressed lower level of E-cadherin and higher levels of N-cadherin, Vimentin and Snail compared to the parental A549P and H157P cells, and exhibited stronger capabilities of metastatic potential compared to the parental cells. The ATM expression was upregulated in A549CisR and H157CisR cells and cisplatin treatment also upregulated expression of ATM in parental cells, The inhibition of ATM by using specific ATM inhibitor CP466722 or knock-down ATM by siRNA suppressed Epithelial-to-Mesenchymal transition (EMT) and metastatic potential of A549CisR and H157CisR cells. These data suggest that ATM mediates the cisplatin-resistance in lung cancer cells. Expressions of JAK1,2,、 STAT3 、PD-L1 and ATM were increased in A549CisR and H157CisR cells and could by induced by cisplatin in parental lung cancer cells. Interestedly, ATM upregulated PD-L1 expression via JAK1,2/STAT3 pathway and inhibition of ATM decreased JAK/STAT3 signaling and decreased PD-L1 expression. The treatment of PD-L1 neutralizing Ab reduced EMT and cell invasion. Inhibition of JAK1,2/STAT3 signaling by specific inhibitors suppressed ATM-induced PD-L1 expression, EMT and cell invasion. Importantly, inhibition of ATM suppressed EMT and tumor metastasis in cisplatin-resistant lung cancer cells in an orthotopic xenograft mouse model.ConclusionsOur results show that ATM regulates PD-L1 expression through activation of JAK/STAT3 signaling in cisplatin-resistant cells. Overexpression of ATM contributes to cisplatin-resistance in lung cancer cells. Inhibition of ATM reversed EMT and inhibited cell invasion and tumor metastasis. Thus, ATM may be a potential target for the treatment of cisplatin-resistant lung cancer.
Highlights
The cisplatin-resistance is still a main course for chemotherapy failure of lung cancer patients
Our results show that Ataxia Telangiectasia Mutated (ATM) regulates PD-L1 expression through activation of Janus kinase (JAK)/STAT3 signaling in cisplatin-resistant cells
epithelial-mesenchymal transition (EMT) and metastatic potential is higher in cisplatinresistant non-small cell lung carcinoma (NSCLC) cells than parental cells We developed two cisplatin-resistant NSCLC cell lines, A549cisR and H157cisR, by treating A549P and H157P cells with a gradually increasing dose of cisplatin over 6 months [14]
Summary
The cisplatin-resistance is still a main course for chemotherapy failure of lung cancer patients. We investigated the effects of Ataxia Telangiectasia Mutated (ATM) on lung cancer metastasis. Cisplatin has been demonstrated to be an effective drug for lung carcinoma treatment effect, but it will develop drug-resistance later on [3, 4]. We have previously found that ataxia telangiectasia mutated (ATM), a member of the phosphatidylinositol 3-kinase-related kinase family of Ser/Thr protein kinases, was induced by accumulated stimulation of cisplatin and was overexpressed in cisplatin-resistant NSCLC. Accumulated data showed that chemo-resistance development is correlated with EMT process [5]. Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition [6]. The results indicate that EMT is associated with development of drug-resistance
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Experimental & Clinical Cancer Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.